How caveolin-1 helps protect the blood‑retina barrier
Role of Caveolin-1 in the Maintenance of Blood-retinal Barrier Integrity
This research explores whether changing the caveolin‑1 protein in retinal support cells can reduce inflammation and help protect vision in retinal inflammatory conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-11179487 on NIH RePORTER |
What this research studies
Researchers are studying a protein called caveolin‑1 (Cav1) that helps maintain the barrier between blood and the retina and appears increased in inflamed retinal diseases. They have identified Cav1 gene variants linked to glaucoma and seen higher Cav1 levels in uveitis and diabetic retinopathy, and in lab models they remove Cav1 from Müller glia to see how inflammation and immune cell entry change. The team uses cell and animal models and plans local approaches such as AAV‑based delivery to manipulate Cav1 function in the retina. The aim is to find ways to lower harmful inflammatory signals and protect retinal tissue without relying on systemic steroids.
Who could benefit from this research
Good fit: People with retinal inflammatory conditions such as uveitis, diabetic retinopathy, or glaucoma linked to Cav1 variants would be the most relevant candidates for this research.
Not a fit: Patients whose vision loss is due mainly to non-inflammatory causes, long-standing scarring, or irreversible damage are less likely to receive benefit.
Why it matters
Potential benefit: If successful, this work could lead to targeted treatments that reduce retinal inflammation and protect vision with fewer steroid-related side effects.
How similar studies have performed: Preclinical studies that alter Cav1 in retinal cells and animal models have lowered cytokine release and immune cell influx, but human testing is still limited.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Elliott, Michael H — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Elliott, Michael H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.